|
Austria-Pf-Pf Κατάλογοι Εταιρεία
|
Εταιρικά Νέα :
- Comparison of safety and toxicity of liposomal doxorubicin vs . . .
Liposomal doxorubicin and pegylated liposomal doxorubicin demonstrated favorable toxicity profiles with better cardiac safety and less myelosuppression, alopecia, nausea and vomiting compared with the conventional antracyclines
- Doxorubicin vs Doxorubicin Liposomal Comparison - Drugs. com
Compare Doxorubicin vs Doxorubicin Liposomal head-to-head with other drugs for uses, ratings, cost, side effects and interactions
- A comparison of liposomal formulations of doxorubicin with drug . . .
This review highlights the differences in both toxicity and pharmacokinetic properties between free doxorubicin and the different liposomal formulations, as have been determined in pre-clinical and clinical testing against a number of different human neoplasms
- Whats better: Doxorubicin liposomal vs Doxorubicin? – meds. is
Doxorubicin liposomal vs doxorubicin has been a topic of debate among medical professionals, with some arguing that the liposomal form is better suited for certain patients One of the main contradictions is the difference in how the two forms are absorbed by the body
- Comparison of the adverse event profiles of conventional and liposomal . . .
Doxorubicin (DOX) is an anthracycline widely used for the treatment of solid and hematological tumors The aim of this study was to assess the adverse event profiles of conventional DOX and liposomal DOX This is the first study to evaluate the effect of a liposomal formulation of DOX using spontaneous reporting system (SRS) databases
- Comparison of safety and toxicity of liposomal versus conventional . . .
We compared pharmacokinetics (PK) and efficacy of PEGylated liposomal doxorubicin (PLD) with non-liposomal doxorubicin (NonL-doxo) in an intracranial model of BC
- Comparison of therapeutic efficacy of lipo-doxorubicin and doxorubicin . . .
Since lipo-doxorubicin (Lipodox) has the advantages of longer half-life and lower clearance rate than doxorubicin, it should improve the efficacy of tumor therapy and reduce the normal tissue toxicity of doxorubicin
- Liposome‐encapsulated doxorubicin compared with conventional . . .
The objective of this study was to compare the efficacy and toxicity of the liposome-encapsulated doxorubicin, TLC D-99 (Myocet, Elan Pharmaceuticals, Princeton, NJ), and conventional doxorubicin in first-line treatment of metastatic breast carcinoma (MBC)
- A Comparison of Liposomal Formulations of Doxorubicin with Drug . . .
The two approved liposomal formulations of doxorubicin have significantly different lipid compositions and loading techniques, which lead to both unique pharmacokinetic and toxicity profiles, distinct from those of the unencapsulated form
- A comparison between liposomal and nonliposomal formulations of . . .
It is emphasized that liposomal doxorubicin promotes better toxicology profile than nonliposomal conventional doxorubicin with an increased cost The cost‐effectiveness of liposomal doxorubicin is not well defined as there are very limited studies in this area
|
|